Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sinopharm Group Co ( (HK:1099) ) has provided an announcement.
Sinopharm Group Co. Ltd. announced the resignation of Mr. Li Dongjiu as a non-executive director due to retirement, effective immediately. The board expressed gratitude for his contributions to the company’s development and governance. Concurrently, the board proposed the appointment of Mr. Chen Yuqing as a new non-executive director, subject to shareholder approval. Mr. Chen, who holds significant experience in human resources and management positions at Fosun Pharma, is expected to enhance Sinopharm’s strategic direction and governance.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major player in the pharmaceutical industry, focusing on the distribution and retail of pharmaceutical and healthcare products. The company operates in Hong Kong and is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance.
Average Trading Volume: 7,668,891
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.57B
For an in-depth examination of 1099 stock, go to TipRanks’ Stock Analysis page.